EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Idorsia's Enterprise Value is CHF2,974.4 Mil.
Idorsia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-134.4 Mil. Therefore, Idorsia's EV-to-FCF for today is -22.12.
The historical rank and industry rank for Idorsia's EV-to-FCF or its related term are showing as below:
CHIX:IDIAz'
s EV-to-FCF Range Over the Past 10 Years
Min: -50.72 Med: -5.4 Max: 35.41
Current: -22.12
During the past 10 years, the highest EV-to-FCF of Idorsia was 35.41. The lowest was -50.72. And the median was -5.40.
CHIX:IDIAz's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 14.7
vs CHIX:IDIAz: -22.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-28), Idorsia's stock price is CHF6.7375.
Idorsia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-1.030. Therefore, Idorsia's PE Ratio (TTM) for today is At Loss.
Idorsia (CHIX:IDIAz) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Idorsia's share price for today is CHF6.7375.
Idorsia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Idorsia EV-to-FCF Related Terms
Idorsia EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Idorsia's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:IDIAZ vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Idorsia's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Idorsia's EV-to-FCF falls into.
Idorsia's current Enterprise Value is CHF2,974.4 Mil.
Idorsia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-134.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia (CHIX:IDIAZ) has a EV-to-FCF of -22.12 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #999999 out of 336 companies in the Biotechnology industry.
Is Idorsia's EV-to-FCF too high?
Idorsia's current EV-to-FCF is -22.12. Based on the distribution chart, Idorsia ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Idorsia has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #999999 out of 336 companies for EV-to-FCF. This places Idorsia in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Idorsia and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current EV-to-FCF is -22.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (CHIX:IDIAZ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.80, compared to a current price of CHF6.74 — trading 140.6% above its estimated fair value. The current EV-to-FCF is -22.12. Idorsia's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Idorsia (CHIX:IDIAZ), the current EV-to-FCF is -22.12 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (CHIX:IDIAZ) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.74 is trading 140.6% above its estimated GF Value™ of CHF2.80.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for CHIX:IDIAZ:
EV-to-FCF: -22.12
GF Value™: CHF2.80 vs. price of CHF6.74 (140.6% above fair value)
No single metric tells the full story. See the CHIX:IDIAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
63GF Score
Get the complete analysis for CHIX:IDIAZ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:IDIAZ has been successfully added to your 
